Mcp-Ratiopharm (Metoclopramide)

Metoclopramide blocks dopamine D2 receptors in the brain’s chemoreceptor trigger zone, decreasing nausea signals, and also blocks peripheral D2 receptors in the gut, leading to increased acetylcholine release that stimulates smooth‑muscle contraction and enhances gastric motility.

The appropriate dose of metoclopramide is determined by the prescribing clinician based on the patient’s condition, age, renal function and other individual factors. Dosage regimens are not standardized and should follow the prescriber’s instructions.

Safety data for metoclopramide in pregnancy and lactation are limited. Clinicians must weigh potential benefits against possible risks, and use the medication only if clearly needed. Breastfeeding mothers should consult their healthcare provider before use.

To request Mcp‑Ratiopharm, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metoclopramide differs from agents such as domperidone by acting centrally on dopamine receptors as well as peripherally to increase gut motility. While both improve gastric emptying, metoclopramide’s central action makes it effective for nausea of various origins, but it also carries a higher risk of extrapyramidal side effects.

Store the tablets at ambient temperature, preferably below 25 °C, in the original container to protect them from moisture and light. Keep out of reach of children and do not use if the packaging is damaged.

Mcp‑Ratiopharm tablets are taken orally with a glass of water. They may be taken with or without food, depending on the prescriber’s guidance, and should be swallowed whole rather than crushed or chewed.

The most serious adverse reactions include extrapyramidal symptoms such as dystonia, the potentially irreversible movement disorder tardive dyskinesia, and neuroleptic malignant syndrome, a life‑threatening condition characterized by fever, muscle rigidity and autonomic instability.

Metoclopramide is contraindicated in patients with known hypersensitivity to the drug, those with pheochromocytoma, seizure disorders, or a history of severe extrapyramidal reactions. Caution is also advised for individuals with depression, Parkinson’s disease or gastrointestinal obstruction.